Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Valeant execs outline development plans for taribavirin for hepatitis C, licensing opportunities and goals for ramping up the commercial organization ahead of potential new launches.

You may also be interested in...



Valeant Seeking Return To Growth With New Chief Executive

Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.

Valeant Seeking Return To Growth With New Chief Executive

Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.

Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Execs provide an update on plans for recharging Cesamet following a sluggish launch, and development plans for a new potential entry: retigabine for seizures.

Topics

UsernamePublicRestriction

Register

PS065162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel